Ab Science Revises Trial Timelines After Three Gcp Inspections

A "for cause" GCP sponsor inspection conducted across five days in late September has forced AB Science to restructure its clinical development timeline and accelerate a quality management system overhaul already initiated under new management, a sequence that QA directors and regulatory leads should read as a textbook example of inspection-triggered remediation cascading into trial holds.

The inspection, conducted from September 21 to 25, 2026, involved five inspectors from France, Denmark, and Greece. Preliminary findings, disclosed at the close of the inspection, validated the new management's July 13 decision to prioritise rebuilding the quality management system and reassessing clinical trial protocols on scientific merit rather than financial timelines. The final inspection report is expected before year-end, at which point AB Science will communicate any further consequences for its development plan.

The revised development plan proceeds in three sequential steps. First, AB Science will complete implementation of the new quality management system and commission an external audit before any clinical studies resume, work the company expects to finish by end of 2026. Second, the Phase 1 study in acute myeloid leukemia (compound AB8939) is targeted for resumption in Q1 2027, contingent on a positive benefit-risk assessment by health authorities and confirmation from the final inspection report. Third, the Phase 3 masitinib study in amyotrophic lateral sclerosis is planned to resume in Q4 2027, following a new inspection, a further condition that extends the remediation burden beyond internal QMS closure.

For sponsor oversight frameworks, the sequencing is operationally significant: resumption of the ALS Phase 3 is explicitly conditioned on passing a follow-up inspection, not merely on submitting a corrective action response. The masitinib program in sickle cell disease is reported as unaffected. AB Science is also using the enforced pause to optimise the AB8939 Phase 1 Step 4 design, refining combination treatment choices and patient selection criteria, and to enrich the ALS Phase 3 protocol through biomarker integration and pre-specification in the statistical analysis plan, changes consistent with ICH E6(R3) expectations around data integrity and protocol robustness.

The company's half-year financial report is due by October 9, 2026, and will be followed by a webcast outlining revised strategic ambitions, the first public financial disclosure under the new management structure.

Confirmation of the AB8939 Phase 1 resumption timeline remains contingent on the final inspection report and the adequacy of AB Science's formal responses to the health authorities.

Source: AB Science via GlobeNewswire, September 29, 2026. Half-year financial report webcast scheduled to follow publication by October 9, 2026.